Cargando…
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Under clinical development since the early 90's and with two successfully approved drugs (Fomivirsen and Mipomersen), oligonucleotide-based therapeutics has not yet delivered a clinical drug to the market in the cancer field. Whilst many pre-clinical data has been generated, a lack of understan...
Autores principales: | Moreno, Pedro M. D., Pêgo, Ana P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196572/ https://www.ncbi.nlm.nih.gov/pubmed/25353019 http://dx.doi.org/10.3389/fchem.2014.00087 |
Ejemplares similares
-
Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene
por: Kralovicova, Jana, et al.
Publicado: (2016) -
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021) -
In vivo and in vitro studies of antisense oligonucleotides – a review
por: Kilanowska, Anna, et al.
Publicado: (2020) -
Progress and Hurdles of Therapeutic Nanosystems against Cancer
por: Martín-Contreras, Marina, et al.
Publicado: (2022) -
Analysis of antisense oligonucleotides with the use of ionic liquids as mobile phase modifiers
por: Kaczmarkiewicz, Anna, et al.
Publicado: (2019)